Transplant activity by members of the European Group for Blood and Marrow Transplantation (EBMT) and related European teams is reported for 1996 by indication, donor type and stem cell source. Bearing in mind reports from previous years, the annual numbers of transplants for each indication, transplant rates for each participating country, changes in transplant rates by indication and changes in donor types and stem cell sources are described. A total 14 593 blood or marrow transplants, performed in Europe by 382 teams from 31 countries, were reported in 1996. Of these, 4393 (30%) were allogeneic and 10 200 (70%) were autologous transplants. Of the autologous transplants, 978 (10%) were bone marrow derived, 9222 (90%) from peripheral blood stem cells or combined bone marrow and peripheral blood stem cell transplants. Of the allogeneic transplants, 3252 (74%) were bone marrow and 1141 (26%) were peripheral blood stem cell transplants. Main indications in 1996 were leukemias with 4961 transplants (34%), 70% allogeneic and 30% autologous; lymphomas with 5505 transplants (38%), 6% allogeneic and 94% autologous; solid tumours with 3484 transplants (24%), 1% allogeneic and 99% autologous; non-malignant disorders with 643 transplants (4%), 92% allogeneic and 8% autologous. There are major differences between countries. Transplant rates per 10m inhabitants per country ranged from 0 to Ͼ500 (median 202 per 10 m inhabitants). The most pronounced increase since 1990 for new indications in autologous transplants was observed in multiple myeloma and carcinoma of the breast. These data reflect recent changes and present status of blood and marrow transplantation in Europe. They provide a basis for patient counselling and health care planning. Keywords: bone marrow transplantation; peripheral blood stem cell transplantation; epidemiology; transplant activity; Europe; coefficient of variation Major developments have occurred in the field of hematopoetic stem cell transplantation since the first successful transplants from HLA-identical siblings in 1968.
Major developments have occurred in the field of hematopoetic stem cell transplantation since the first successful transplants from HLA-identical siblings in 1968. 1, 2 The formerly experimental procedure has become established therapy for a vast number of congenital or acquired disorders of the hematopoietic system and for chemo-or radiosensitive malignancies. [3] [4] [5] [6] Reduced transplant-related mortality has led to a widening of indications. The rapid increase in utilization of this technique over the past few years has been documented by the surveys of the International Bone Marrow Transplant Registry (IBMTR) 7, 8 and annual transplant activity report of the European Group for Blood and Marrow Transplantation (EBMT). [9] [10] [11] [12] [13] [14] Traditional bone marrow transplantation has been supplemented by transplantation of hematopoetic stem and progenitor cells from different stem cell sources and donor types. Blood and marrow transplantation today includes autologous and allogeneic transplants from bone marrow, peripheral blood, cord blood and, occasionally, fetal liver as a stem cell source. Donors for allogeneic transplants can be HLA-identical siblings, HLAmismatched relatives or unrelated volunteers. The present report, the seventh of a series, summarizes transplant activity in Europe in 1996. It concentrates on the rapid changes in stem cell source, donor type and indications since 1990, when the EBMT activity survey was first introduced. Awareness of these changes is essential for correct interpretation of current data.
Patients and methods

Activity survey
All EBMT members are requested to report their transplant numbers annually for the preceding year by indication, stem cell source and donor type ( Table 1 ). The same questionnaire is sent to non-members, known to the investigators to perform transplants, and to teams made known to EBMT by national organisations, neighboring teams or hospital administrators. The first survey was conducted for 1990. 9 In 1993, all participating teams were additionally requested to report their transplant numbers selectively for 1973 and 1983 . These data have been published. 12 Numbers of transplant patients rather than numbers of transplants are coun- 19  3465  3484  Neuroblastoma  1  1  -----1  4 5  1 5 3  1 7  3  2 1 5  2 1 8  Glioma  --------2 1  1 9  3  -4 3  4 3  Soft tissue sarcoma  --------8  8 7  6  -1 0 1  1 0 1  Germinal tumors  1  1  ---1  --20  306  9  3  335  338  Breast carcinoma  1  3  ------1 7  2175  17  4  2209  2213  Ewing  -1  --1  1  --3  161  2  3  166  169  Other solid tumors  2  3  -----1  1 5  3 7 1  1 0  6  3 9 6  4 0 2  Non-malignant disorders  590  53  643  Severe aplastic anemia + Fanconi  137  29  8  5  1  1  26  9  ---216  -216  Thalassemia  96  6  --------1 0 2  -1 0 2  SCID  19  7  16  12  --6  1  ---61  -61  Inborn errors  50  4  14  8  --48  4  ---128  -128  Others  41  13  5  7  1  -14  2  4  47  2  83  53  136  Total  2198 849 165 189  17  22  872  81  978  8897  325  4393 10200 14593 HLA-id = identical sibling donor; Non-id = family donor other than HLA-identical sibling; BM = bone marrow; PBPC = peripheral precursor blood cells; Both = bone marrow + peripheral precursor blood cells; Allo = total allogeneic transplants; Auto = total of autologous transplants.
ted omitting second, double, or re-transplants. Stem cell source has been included as a variation since 1991.
Participating teams
382 teams from 31 European countries and, by EBMT tradition, teams from Israel and Saudi Arabia report all consecutive allogeneic and autologous transplants. They are listed in the Appendix in alphabetical order of country, town, center and reporting physician. According to personal communications, no blood or marrow transplants were performed in 1996 in Albania, Andorra, Armenia, Azerbaijan, Bosnia-Herzegovina, Bulgaria, Cyprus, Georgia, Iceland, Latvia, Liechtenstein, Lithuania, Macedonia, Malta, Moldovia, Monaco, Romania, San Marino, Ukraine and the Vatican.
Data validation
Reported data are entered in a computer file. Before data analysis, a printout is sent to each team for validation and verification. In countries with a national transplantation agency or registry, data are compared with the respective national coordinators. Discrepancies between reports to the national agency and EBMT are corrected by contacting teams in question for rectification. Eight teams reporting in 1995 failed to reply to the 1996 survey. These are listed in the Appendix as 'missing'. According to our estimate, the report covers 95% of all allogeneic and probably almost 90% of all autologous blood or marrow transplants performed in Europe in 1996.
Statistical analysis
Relative transplant activity per 10m inhabitants, ie transplant rate, was calculated for participating countries by computing the number of teams and transplants against the number of inhabitants, as taken from the Fischer's Weltalmanach 15 (Table 2 ). Calculations were made for all transplants and then separately for allogeneic, autologous and unrelated transplants.
The coefficient of variation (CV), defined as CV (%) = (s.d./mean) × 100, was used as a measure of homogeneity among participating countries and to quantitatively assess consensus for certain indications as previously described. 16, 17 The number of transplants per 10m inhabitants was calculated for each indication and European country with at least 100 transplants in 1995 and 1996. These include Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, The Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and UK. Indications considered were acute myeloid, acute lymphoid and chronic myeloid leukemia and myelodysplastic syndromes; Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma for lymphoproliferative disorders; neuroblastoma, germ cell tumors and carcinoma of the breast for solid tumors; severe aplastic anemia and thalassemia for non-malignant disorders. The coefficient of variation in transplant rates between these 16 countries was determined for all these indications and for each survey year since 1990.
Mean, median, range and coefficient of variation of numerical variables were calculated with the Excel spreadsheet. Regression analysis to evaluate changes over time and correlation to evaluate associations were applied where appropriate.
Results
Participating teams
382 participating teams from 31 countries reported to the survey in 1996. Since the first survey in 1990, numbers of participating teams has risen from 143 to 382, almost exclusively due to new teams starting transplant activities. The current report includes all teams reporting to the 1995 survey except for nine (response rate 98%).
The majority of teams, ie 251/382 (66%), do both allogeneic and autologous transplants, 124 (32%) of teams restrict their activity to autologous, five (2%) to allogeneic transplants only (Table 2) .
Transplant figures
A total 14 593 transplants, 4393 allogeneic (30%) and 10 200 autologous (70%) were carried out in 1996. This represents an increase of 18% over 1995, when there were 12 101 transplants (3858 allogeneic, 8243 autologous). This increase is due to new teams (8% increase) and greater numbers of transplants by established teams.
The rise in transplant activity with 16 transplants from 1973, 1353 transplants in 1983 and a further increase since 1990, is illustrated in Figure 1 .
Main indications
Indications for transplants in 1996 are listed in detail in Table 1 . Main indications for the 14 593 patients were lymphomas with 5505 transplants (38%), 333 (6%) allogeneic and 5172 (94%) autologous; leukemias with 4961 transplants (34%), 3451 (70%) allogeneic and 1510 (30%) autologous; solid tumors with 3484 transplants (24%), 19 (1%) allogeneic and 3465 (99%) autologous and non-malignant disorders with 643 transplants (4%), 590 (92%) allogeneic and 53 (8%) autologous. The relative proportion of indications has remained constant for allogeneic transplants; there has been a shift in main indications for autologous transplants with an increase in solid tumors from 18% (377/2097) in 1990 to 34% (3465/10 200) of all autologous transplants in 1996 (P Ͻ 0.01).
Donor type
Of the 14 593 transplants in 1996, 4393 were allogeneic (30%) and 10 200 autologous (70%). For the 4393 allogeneic transplants, donors were an HLA-identical sibling (70%) for 3047 recipients, HLA non-identical family member (8%) for 354 recipients, syngeneic twin (1%) for 39 recipients and an unrelated, volunteer donor (22%) for 953 recipients. Changes in donor type for the allogeneic trans- plants since 1990 are illustrated in Figure 2 . The proportion of unrelated transplants has increased from less than 1% in 1983 to 181 (8.5%) in 1990 and 953 (22%) in 1996. 12 The most frequent indications for unrelated allogeneic transplants are chronic myeloid leukemia in chronic phase, acute leukemias beyond first complete remission and congenital disorders.
Stem cell source
Of the 10 200 autologous transplants, 978 (10%) were bone marrow derived, 8897 (87%) from peripheral blood and 325 (3%) combined bone marrow and peripheral blood cells. In 1991, the proportion of autologous bone marrow-derived cells was 85%. This rapid shift in donor source is illustrated in Figure 3 .
In 1991, no allogeneic peripheral blood stem cell transplants were reported. In 1996, 3252 (74%) of the 4393 allogeneic transplants were bone marrow derived, 1141 (26%) used peripheral blood stem cells. The proportion of unrelated peripheral blood stem cell transplants is low (81/953, 8%) compared to 28% for the HLA-identical sibling donors, 54% for related non-identical donors and 59% for 1990 1991 1992 1993 1994 1995 1996 twin donors. This change, occurring since 1991, is illustrated in Figure 3 .
A total 71 allogeneic cord blood transplants were reported. This represents 2% of all allogeneic transplants in 1996. Detailed figures of cord blood transplants have only been collected since 1996.
Transplant rates per number of inhabitants
There are significant differences between participating countries, as shown in Table 2 . The number of teams ranges from Ͻ1 to Ͼ10 per 10 m inhabitants. There is no significant correlation between the total number of transplants and the number of teams (r = 0.16; P = 0.39). Transplants per 10 m inhabitants (= transplant rates) range from Ͻ1 (several countries) to 967 (Luxemburg) with a median of 202 per 10 m inhabitants (median of those countries with transplants only) and is illustrated in Figure 4 . In general, differences in transplant rates between participating countries are similar for total transplants as for allogeneic, autologous or unrelated transplants. The high numbers of transplants per 10 m inhabitants in Israel and Luxemburg is in part explained by a high referral rate of non-residents (personal communications).
Variation of transplant rates (coefficient of variation) by indication
The CVs and changes in CVs over time are illustrated for leukemias (Figure 5a ), lymphoproliferative disorders ( Figure 5b ) and solid tumors (Figure 5c ). In general, all CVs have dropped, indicating a progressive consensus. The lowest CVs for allogeneic transplants are found in acute myeloid leukemia (CV 33%), acute lymphoid leukemia (CV 41%) and chronic myeloid leukemia (CV 44%), for autologous transplants in Hodgkin's disease (CV 41%) and non-Hodgkin's lymphoma (CV 46%). The figures show that carcinoma of the breast, multiple myeloma and chronic myeloid leukemia have become indications for autologous transplantation over the last few years. 1990 1991 1992 1993 1994 1995 1996 1990 1991 1992 1993 1994 1995 1996 1991 1992 1993 1994 1995 1996 
Discussion
The present report, the seventh of a series, [9] [10] [11] [12] [13] [14] gives information on transplant numbers, transplant rates, stem cell sources, donor types and indications for blood and marrow transplants in Europe. It illustrates four major trends of the last 7 years. The number of transplants of blood and marrow progenitor cells is increasing rapidly, there is a shift from bone marrow to peripheral blood-derived cells in both autologous and allogeneic transplants, unrelated donor transplants are used increasingly and new indications for autologous transplants are emerging.
The report underlines the rapid evolution of blood and marrow transplantation from an experimental undertaking 30 years ago 1, 2 to an established procedure today. More than 14 000 transplants were performed last year in Europe, an estimated total of 30 000 worldwide. This evolution appears unbroken despite increasing economic difficulties facing the health care system. The trend is likely to continue. Recent publications of prospective controlled randomized studies document the therapeutic benefit of highdose therapy and autologous stem cell transplants. [18] [19] [20] Several studies are in progress. There is evidence to support the concept of an allogeneic graft vs tumor response.
21
Unrelated donor transplants have become an established procedure, 22 donor registries continue to grow and cord blood is emerging as an additional source of stem cells for patients without donors.
23-25
There has been a rapid shift from bone marrow to peripheral blood in a short period. Only 10 years ago, almost all transplants were bone marrow derived. Autologous peripheral blood precursor cell collection is relatively easy. These transplants engraft rapidly and reliably.
26 Autologous bone marrow transplants will remain restricted to the few patients unable, or unwilling, to undergo peripheral harvesting. In the allogeneic setting, fear of excessive graftversus-host disease and reluctance to use mobilization techniques has long precluded the use of peripheral blood precursor cells. 27 Single centre pilot studies and retrospective multicenter analyses have confirmed feasibility.
28-31 A prospective randomized controlled study showed more rapid recovery and no adverse effects on short-term outcome as compared to allogeneic bone marrow transplants.
32 Effects on long-term outcome, such as chronic graft-versus-host disease, relapse and survival, as well as effects of mobilization on donors are still unknown. If preliminary data are confirmed, donors will have the choice between bone marrow harvest with its risks from anesthesia, or peripheral blood donation and its mobilization risk. 33 Teams in many countries also offer this possibility to unrelated volunteer donors.
22
The relative ease and safety of autologous peripheral blood transplants, with transplant-related mortality under 5%, has led to new indications. 34 Multiple myeloma has emerged as an indication for autologous transplantation, documented in prospective randomized trials and illustrated in this report. 20 Carcinoma of the breast is at present the most frequent single indication for autologous transplantation in solid tumors. Ongoing prospective randomized trials will help to determine its place. New, previously undermined indications, such as severe autoimmune disorders, are now under scrutiny.
35,36
The current analysis confirms previously observed discrepancies between Western and Eastern Europe, partly reflecting differences in economic status. 10 It remains a challenge to supply modern medical technology to all countries, and it is comforting to note increasing activity in some Eastern European countries.
Varying prevalence of disease can explain differences in transplant rates for some indications, eg thalassemia. In contrast, prevalence does not differ significantly for most hematological malignancies. 36 Other reasons, including heterogeneity in medical opinion, can explain part of the differences. The CV in transplant rates provides an instrument for assessing consensus in an objective quantitative way.
37
During the observation period, CVs have decreased for most indications and lowest CVs are found for the indications recommended by expert panels. 6 The optimal time point for procedure remains debatable, eg should a transplant be performed in first or subsequent remission for a patient with acute myeloid leukemia. Answers to these questions depend on disease, patient and donor factors.
This report provides no information on outcome, for which data are being collected and will be reported with due follow-up.
14 Awareness of the most significant changes in recent years will be essential for analysis and interpretation of outcome. Knowledge of current activity and ongoing trends form a basis for health care planning and for setting up guidelines and recommendations for patient counselling. 14 Gratwohl A. Special 
Appendix 1996
List of transplant centres and numbers of transplants performed (numbers in brackets show total number of transplants followed by allografts/autografts) 
